Abstract
Background: Identifying robust neural signatures of posttraumatic stress disorder (PTSD) symptoms is important to facilitate precision psychiatry and help in understanding and treatment of the disorder. Emergent research suggests structural covariance of early visual regions is associated with later PTSD development. However, large-scale analyses are needed, in heterogeneous samples of trauma-exposed and trauma naive individuals, to determine if such a neural signature is a robust, and potentially a pretrauma, marker of vulnerability. Methods: We analyzed data from the ENIGMA-PTSD dataset (n = 2,814) and the Human Connectome Project Young Adult (HCP-YA) dataset (n = 890) to investigate whether structural covariance of early visual cortex is associated with either PTSD symptoms or perceived stress. Structural covariance was derived from a multimodal pattern previously identified in recent trauma survivors, and participant loadings on the profile were included in linear mixed effects models to evaluate associations with stress. Results: Early visual cortex covariance loadings were negatively associated with PTSD symptoms in the ENIGMA-PTSD dataset. The relationship persisted when accounting for prior childhood maltreatment; supporting PTSD symptom specificity, no relationship was observed with depressive symptoms and no association was observed between loadings and perceived stress measures in the HCP-YA dataset. Conclusion: Structural covariance of early visual cortex was robustly associated with PTSD symptoms across an international, heterogeneous sample of trauma survivors. Future studies should aim to identify specific mechanisms that underlie structural alterations in the visual cortex to better understand posttrauma psychopathology.
Competing Interest Statement
Over the past 3 years, Dr. Pizzagalli has received consulting fees from Arrowhead Pharmaceuticals, Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Karla Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Sage Therapeutics, and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Dana Foundation, Millennium Pharmaceuticals, NIMH, and Wellcome Leap; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. Dr. Lebois reports unpaid membership on the Scientific Committee for the International Society for the Study of Trauma and Dissociation (ISSTD), grant support from the National Institute of Mental Health, K01 MH118467, spousal IP payments from Vanderbilt University for technology licensed to Acadia Pharmaceuticals, and spousal employment at Violet Therapeutics, all unrelated to the present work. Dr. El-Hage reports payments from Air Liquide, CHUGAI, EISAI, Jazz Pharmaceuticals, Janssen, Lundbeck, Otsuka, UCB unrelated to the present work. Dr. Herringa reports consultancy work for Jazz Pharmaceuticals. Dr. Davidson is the founder and president of, and serves on the board of directors for, the non-profit organization Healthy Minds Innovations, Inc. Dr. Abdallah has served as a consultant, speaker and/or on advisory boards for Douglas Pharmaceutical, Freedom Biosciences, FSV7, Lundbeck, Psilocybin Labs, Genentech, and Janssen; and received royalties for a patent on using mTOR inhibitors to augment the effects of antidepressants (filed on August 20, 2018). Dr. Olsen reports employment at CrisisHealthLine. All other authors report no conflicts of interest or relevant disclosures. All views expressed are solely those of the authors.
Funding Statement
The present work was funded by: National Institute of Mental Health (K01MH129828) and the Brain Behavior Research Foundation (NGH), R21MH112956, R01MH119227, McLean Hospital Trauma Scholars Fund, Barlow Family Fund, Julia Kasaparian Fund for Neuroscience Research, R01MH111671, R01MH117601, R01AG059874, MJFF 14848, ZonMw, the Netherlands organization for Health Research and Development (40.00812.98.10041), and the Academic Medical Center Research Council (110614), the National Natural Science Foundation of China (No. U21A20364 and No. 31971020), the Key Project of the National Social Science Foundation of China (No. 20ZDA079), the Key Project of Research Base of Humanities and Social Sciences of Ministry of Education (No.16JJD190006), and the Scientific Foundation of Institute of Psychology, Chinese Academy of Sciences (No. E2CX4115CX), NARSAD 27040, NIMH K01 MH122774, NIMH K01 MH118428.01, RO1 MH111671, VISN6 MIRECC, MH098212, MH071537, M01RR00039, UL1TR000454, HD071982, HD085850, Narsad Young Investigator, K01MH121653, MH101380, German Research Foundation grant to J. K. Daniels (numbers DA 1222/4.1 and WA 1539/8.2), the Ministry of Health of the Czech Republic, grant no. AZV NV18.7 04.00559, MAFIL supported by the Czech.BioImaging large RI project (LM2023050 funded by MEYS CR), K23MH112873, R01MH113574, VA RRD 1K1RX002325, 1K2RX002922, VA RR&D I01RX000622, CDMRP W81XWH.08.2.0038, German Research Society (Deutsche Forschungsgemeinschaft, DFG, SFB.TRR 58: C06, C07), The Natural Science Foundation of Jiangsu Province (No. BK20221554), and the Foundation for the Social Development Project of Jiangsu (No. BE2022705), PHRC, Fondation Pierre Deniker and SFR FED4226, R01.MH132221, R01.MH128371, Dana Foundation (to Dr. Nitschke), the University of Wisconsin Institute for Clinical and Translational Research (to Dr. Emma Seppala), a National Science Foundation Graduate Research Fellowship (to Dr. Grupe), the National Institute of Mental Health (NIMH) R01.MH043454 and T32.MH018931 (to Dr. Davidson), and a core grant to the Waisman Center from the National Institute of Child Health and Human Development (P30.HD003352), R01 MH106574, R21MH106998, VA CSR&D 1IK2CX001680, VISN17 Center of Excellence Pilot funding, the SAMRC Unit on Risk & Resilience in Mental Disorders, R01MH105355.01A, grant 01J05415 from the Special Research Fund (BOF) at Ghent University, VA RR&D 1IK2RX000709, 1R01MH110483 and 1R21MH098198, VA National Center for PTSD, The Beth K and Stuart Yudofsky Chair in the Neuropsychiatry of Military Post Traumatic Stress Syndrome, Department of Defense award number W81XWH.12.2.0012, ENIGMA was also supported in part by NIH U54 EB020403 from the Big Data to Knowledge (BD2K) program, R56AG058854, R01MH116147, R01MH111671, and P41 EB015922, RO1 MH111671, VISN6 MIRECC
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants included in this analysis came from two datasets: The ENIGMA-PGC PTSD Working Group and the Human Connectome Project Young Adult. ENIGMA is an international data sharing consortium. Participants for each contributing study provided informed consent with each study approved by the respective institutional review board. Participants in the Human Connectome Project gave informed consent as approved by the Washington University in St Louis Human Research Protection Office.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos